secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2024-10-28T23:59:59+00:00
Accession:  0001213900-24-091172
Event type: other
Sentiment:  positive
Materiality: 0.40
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed files PCT patent application for INM-901 treating Alzheimer's and neurodegeneration
--------------------------------------------------------------------------------

- PCT patent covers composition, method of use for INM-901 in neurodegenerative diseases including Alzheimer's.
- Patent claims neuroprotection, neurite elongation, cognitive/memory improvement, and anti-inflammatory effects.
- InMed now has 14 patent families; eight on drug composition/formulations, six on manufacturing technologies.
- Company plans to present long-term in vivo data for INM-901 in coming weeks.
- INM-901 is an oral small molecule with CB1/CB2 and PPAR activity, targeting multiple Alzheimer's pathways.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024091172/0001213900-24-091172-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024091172/ea0218824-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-091172

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer